IMM: Net loss increased to £4.7 million, but fundraising extends cash runway to H2 2028

Operating loss narrowed to £1.1 million, but net loss rose to £4.7 million due to a derivative asset revaluation. £6.47 million was raised to fund Kapiglucagon and P140, extending cash runway to H2 2028. Focus remains on advancing both assets and securing a P140 commercial deal in 2026.Original doc…